A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors
Latest Information Update: 02 Jul 2024
At a glance
- Drugs BLU 222 (Primary) ; Carboplatin (Primary) ; Fulvestrant (Primary) ; Ribociclib (Primary)
- Indications Advanced breast cancer; Endometrial cancer; Gastric cancer; HER2 negative breast cancer; Ovarian cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Acronyms VELA
- Sponsors Blueprint Medicines
- 04 Jun 2024 Results assessing safety and efficacy were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 23 May 2024 Results presented in the Blueprint Medicines Media Release.
- 02 May 2024 According to a Blueprint Medicines media release, data from this study will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.